Quoin Pharmaceuticals Ltd - יחס שווי כולל של החברה להכנסות QNRX

Quoin Pharmaceuticals Ltd (QNRX) - לוגו תאגידי

The enterprise value-to-revenue ratio displayed by the GURU.Markets system helps assess the strategy of Quoin Pharmaceuticals (QNRX) in developing unique treatments for fatal genetic skin pathologies. 0.00 captures the magnitude of this parameter while the company spends working capital on pre-commercial tests. High loyalty among the staff of biochemists and dermatologists ensures success in treating rare dermatological diseases.

QNRX: שווי חברה להכנסות Quoin Pharmaceuticals Ltd. 23.11.2025 - 20.11.2026

Quoin Pharmaceuticals Ltd. - פילוחים אנליטיים ומדדי מפתח (QNRX)

- מדדי מזומנים ותזרימי מזומנים:
הערכת שווי פונדמנטלית של החברה:QNRX - Quoin Pharma
פריט של המותג quoinpharma.com

The scale of drug development for rare dermatological pathologies under conditions of geopolitical neutrality makes the EV-to-revenue ratio a key indicator of the business's objective value. This metric compares the total market price of assets with sales volume, excluding the impact of debt load, which allows investors to assess the fundamental maturity of Quoin Pharmaceuticals (QNRX) and the stability of its market capitalization.